Ana Bocanegra

Functional systemic <scp>CD</scp> 4 immunity is required for clinical responses to <scp>PD</scp> ‐L1/ <scp>PD</scp> ‐1 blockade therapy

Miren Zuazo, Hugo Arasanz, G. Fernández-Hinojal et al. · EMBO Molecular Medicine · 2019 · 211 citations · Full text

Effective cancer immunotherapy in mice by polyIC-imiquimod complexes and engineered magnetic nanoparticles

Ana Bocanegra, Ane Ruiz‐de‐Angulo, Aintzane Zabaleta et al. · Biomaterials · 2018 · 100 citations · Full text

Nanoparticles, Nanomedicine, Tumor Immunology +12

PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer

Ana Bocanegra, G. Fernández-Hinojal, Miren Zuazo-Ibarra et al. · International Journal of Molecular Sciences · 2019 · 73 citations · Full text

Tumor Immunology, Cancer Immunosurveillance, Pd-l1 Expression +15

Early Detection of Hyperprogressive Disease in Non-Small Cell Lung Cancer by Monitoring of Systemic T Cell Dynamics

Hugo Arasanz, Miren Zuazo, Ana Bocanegra et al. · Cancers · 2020 · 65 citations · Full text

Triple-Labeling of Polymer-Coated Quantum Dots and Adsorbed Proteins for Tracing their Fate in Cell Cultures

Carolina Carrillo‐Carrión, Ana Bocanegra, Blanca Arnáiz et al. · ACS Nano · 2019 · 55 citations

Nanoparticles, Engineering, Colloidal Nanocrystals +18